Abstract |
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
|
Authors | E S Newlands, G J Rustin, M H Brampton |
Journal | British journal of cancer
(Br J Cancer)
Vol. 74
Issue 4
Pg. 648-9
(Aug 1996)
ISSN: 0007-0920 [Print] England |
PMID | 8761384
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Fatty Acids, Unsaturated
- leptomycin B
|
Topics |
- Anorexia
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Fatty Acids, Unsaturated
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Neoplasms
(drug therapy)
|